X

Drug Profile

Ciprofloxacin extended release - Bayer

Alternative Names: Cipro XR; Ciprofloxacin ER - Bayer

Latest Information Update: 04 Dec 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ranbaxy Laboratories
Developer Bayer
Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
Mechanism of Action Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Pyelonephritis; Urinary tract infections

Most Recent Events

26 Jul 2016 The US FDA approved label for ciprofloxacin ER carries a boxed warning
25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com